Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
์ข
๋ชฉ ์ฝ๋ EOLS
ํ์ฌ ์ด๋ฆEvolus Inc
์์ฅ์ผFeb 08, 2018
CEOMoatazedi (David)
์ง์ ์332
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃFeb 08
์ฃผ์520 Newport Center Dr Ste 1200
๋์NEWPORT BEACH
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ92660-7022
์ ํ19492844555
์น์ฌ์ดํธhttps://www.evolus.com/
์ข
๋ชฉ ์ฝ๋ EOLS
์์ฅ์ผFeb 08, 2018
CEOMoatazedi (David)